In pre-clinical studies, blockade of CTLA-4 led to rejection of lymphoma, colorectal, renal and fibrosarcoma cancer cell lines in mice [285] and activation of human tumour-specific CTLs [286]. This evidence concerns the gene CTLA4 and cancer.